| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S00520-017-3610-2 |
| P8608 | Fatcat ID | release_hrxfno5kgnebrhuytfeck6bstu |
| P698 | PubMed publication ID | 28204995 |
| P50 | author | Philippe Debourdeau | Q57117166 |
| George Dranitsaris | Q92696583 | ||
| P2093 | author name string | Gunar Stemer | |
| Lesley G Shane | |||
| Seth Woodruff | |||
| Jean-Philippe Galanaud | |||
| P2860 | cites work | Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines | Q24633010 |
| Review of the cost of venous thromboembolism | Q26781947 | ||
| Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer | Q28186303 | ||
| Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinib | Q33387073 | ||
| Development of WHO guidelines on generalized cost-effectiveness analysis | Q33903387 | ||
| Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines | Q34215315 | ||
| Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update | Q34719264 | ||
| Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States | Q36617694 | ||
| A post hoc analysis of dalteparin versus oral anticoagulant (VKA) therapy for the prevention of recurrent venous thromboembolism (rVTE) in patients with cancer and renal impairment | Q37293267 | ||
| Assessing risk of venous thromboembolism in the patient with cancer. | Q37393394 | ||
| The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients with breast cancer in the UK. | Q37607276 | ||
| Health technology assessment of cancer drugs in Canada, the United Kingdom and Australia: should the United States take notice? | Q38255974 | ||
| Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial | Q38405764 | ||
| Utility approach to measuring health-related quality of life | Q39659272 | ||
| Cost-utility analysis of palonosetron-based therapy in preventing emesis among breast cancer patients. | Q39790060 | ||
| Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study | Q39949914 | ||
| The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. | Q44604237 | ||
| Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients | Q45079373 | ||
| The cost of thromboembolic events in hospitalized patients with breast or prostate cancer in France | Q46099414 | ||
| Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States. | Q47262610 | ||
| The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects | Q47270215 | ||
| Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study | Q48661559 | ||
| Alternatives to the QALY measure for economic evaluations. | Q53603111 | ||
| Clinical and economic impact of epoetin in adjuvant-chemotherapy for breast cancer | Q79794344 | ||
| Criteria for deciding cost-effectiveness for expensive new anti-cancer agents | Q81099562 | ||
| Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy | Q86444584 | ||
| P433 | issue | 7 | |
| P921 | main subject | vitamin K | Q182338 |
| (E)-phytonadione | Q186093 | ||
| venous thromboembolism | Q9397786 | ||
| Austria | Q40 | ||
| P304 | page(s) | 2093-2102 | |
| P577 | publication date | 2017-02-15 | |
| P1433 | published in | Supportive Care in Cancer | Q15766919 |
| P1476 | title | Dalteparin or vitamin K antagonists to prevent recurrent venous thromboembolism in cancer patients: a patient-level economic analysis for France and Austria | |
| P478 | volume | 25 |
| Q38600392 | Low-molecular-weight heparins for the prevention of recurrent venous thromboembolism in patients with cancer: A systematic literature review of efficacy and cost-effectiveness. |
| Q61797453 | Recent Advances in the Management of Cancer-Associated Thrombosis: New Hopes but New Challenges |
Search more.